SMARCB1 and sarcoma: Assessing the dose-response effects of ponatinib in the panel of 17 cell lines, consisting of five SMARCB1-deficient cell lines (A204, G402, G401, BT12, and CHLA226) and 12 wild-type sarcoma cell lines, confirmed that cells with SMARCB1 deficiency were sensitive to this TKI (Figure 3F).